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Abstract 
The aim of the present study is to determine the expression levels of PYHIN (IFI16 and 
AIM2) and APOBEC3 (A3A, A3B, A3C, A3D, A3F, A3G, and A3H) gene family members 
in a cohort of patients with head and neck squamous cell carcinoma (HNSCC) and assess 
their potential correlation with human papillomavirus (HPV) infection status, clinical 
characteristics, and survival. For this purpose, 34 HNSCC tissue specimens along with 
healthy surrounding mucosa were collected from patients surgically treated for HNSCC. 
Nucleic acids were isolated to assess the presence of HPV and the expression levels of 
selected molecular markers. Survival analysis was carried out using the Kaplan-Meier 
method. In HPV-negative (HPV-) HNSCCs, we detected low mRNA expression levels of 
IFI16, A3A, and A3B, whereas these genes were upregulated 2-100 folds in HPV-positive 
(HPV+) tumors (p<0.05). Interestingly, AIM2 gene expression levels were predominantly 
unchanged in HPV+ HNSCCs compared to their HPV- counterparts, in which AIM2 was 
predominantly upregulated (10% vs 50% of patients). In HPV- tumors, upregulation of TP53, 
NOTCH1, PD-L1, and IFI16 correlated with lower occurrence of nodal metastases. On the 
other hand, the expression of APOBEC family members did not correlate with clinical 
characteristics. Regarding survival, patients with upregulated A3F gene expression had a 
worse prognosis, while patients without changes in A3H expression had a lower survival rate. 
In conclusion, our findings indicate that the innate immune sensors IFI16 and AIM2 and some 
APOBEC family members could be potentially used as biomarkers for disease outcome in 
HNSCC patients regardless of HPV presence.  
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Introduction 
 Head and neck cancer is the sixth most common type of cancer and represents about 
6% of all cases of tumors worldwide. Its incidence is 15.2 and 4.6 per 100,000 people in 
males and females, respectively [1]. Approximately 90% of all head and neck tumors, which 
arise predominantly in the mucosa of the oral cavity, pharynx, and larynx, are histologically 
classified as squamous cell carcinomas (HNSCCs).  
Human papillomavirus (HPV), alongside other risk factors such as alcohol and 
tobacco consumption, is emerging as an important etiological factor of HNSCC. In this 
regard, HPV positivity correlated with an increasing incidence rate of oropharyngeal cancers 
in men younger than age 50 without a history of tobacco use, with HPV type 16 (HPV16) 
being the most commonly found high risk HPV in these HNSCCs [2]. Fittingly, high-risk 
HPV types have been detected in 45-70% of oropharyngeal cancers [3]. Intriguingly, different 
prognosis has been reported for and HPV-negative (HPV-) vs. HPV-positive (HPV+) 
HNSCCs. In particular, as HPV infection seems to be associated with a better response to 
therapy and survival [2], some authors have proposed a treatment deintensification for HPV+ 
patients [4]. Despite significant progress in HNSCC disease management, the prognosis of 
recurrent HNSCCs still remains poor in most cases [5].  
 A number of HNSCC biomarkers have been identified over the last few years. These 
include oncogenes and tumor suppressors (e.g. TP53, p16, and NOTCH1), cell cycle 
regulators (e.g. Ki67, cyclin D1, EGFR, K-ras, pSTAT3, and SOX2), base excision repair 
pathway components (e.g. ERCC1, XRCC1), angiogenic factors (e.g. VEGF), and proteins 
involved in the immune response (e.g. PD-L1) [6]. Of note, TP53 and NOTCH1 appear to be 
the most mutated genes [6]. 
The observation that there are different biomarker profiles in HPV- vs. HPV+ HNSCCs 
[7] implies that HPV infection may be directly involved in gene regulation. In this regard, 
4 
 
HPV proteins E6 and E7 contribute to tumorigenesis through TP53 and retinoblastoma 
protein (pRb) inactivation. Loss of pRb activity induces p16 protein expression, regulating the 
progress from the G1 to the S phase of the cell cycle [7]. The immunohistochemical detection 
of p16 is used in routine diagnostics as a surrogate marker for HPV infection. However, its 
overexpression does not correlate univocally with the presence of HPV DNA in HNSCC, so it 
should not be considered as the ideal biomarker for HPV infection. Moreover, HPV+ tumors 
express wild-type TP53 [8]. 
 HPV+ tumors display generally higher expression levels of interferon-inducible protein 
16 (IFI16) compared to HPV- lesions. IFI16, a member of the PYHIN family of proteins, 
[9][10]. In HNSCC, IFI16 exerts an in vivo anti-tumoral activity by promoting apoptosis of 
tumor cells, inhibiting neo-vascularization, and increasing the release of chemotactic factors 
for the recruitment of macrophages [11]. Furthermore, IFI16 has the ability to bind virus-
derived intracellular DNA and then function as a pattern recognition receptor (PRR) 
[12,13,14]. 
 Another member of the PYHIN family and cytoplasmic sensors of double strand DNA 
(dsDNA) of microbial or host origin is absent in melanoma 2 (AIM2), which plays an 
important role in the regulation of the inflammasome. Moreover, AIM2 orchestrates 
inflammasome-independent functions in colorectal cancer by suppressing stem cell 
proliferation [15]. 
 In some human tumors, several mutations have been attributed to abnormal activity of 
DNA-modifying enzymes, including the apolipoprotein B mRNA editing enzyme catalytic 
polypeptide-like (APOBEC) family of cytidine deaminases [16,17,18,19]. APOBEC 
activation constitutes part of the innate immune response to viruses, including 
cytomegalovirus (CMV), HPV, and hepatitis B virus (HBV) [20,21,22]. APOBEC3A (A3A) 
and APOBEC3C (A3C) proteins can hypermutate the genome of HPV16 and reduce 
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pseudovirion infectivity [21]. Moreover, APOBEC3B (A3B) seems to play a major role in 
HPV+ HNSCC mutagenesis [23]. Different mutational signatures have been found in HPV- vs. 
HPV+ HNSCC, with the former showing a smoking-associated mutational signature, while the 
reduced exposure to exogenous carcinogens in HPV+ tumors creates a selective pressure that 
favors APOBEC-mediated mutations [23]. 
 The primary aim of this study is to evaluate differences in gene expression levels 
between HPV+ and HPV- HNSCCs. For this purpose, we carried out gene expression analysis 
of a number of genes implicated in HPV-induced chronic inflammation and carcinogenesis 
such as the aforementioned innate immune sensors IFI16 and AIM2 and the APOBEC family 
members A3A, A3B, A3C, A3D, A3F, A3G, and A3H. Besides PYHIN and APOBEC genes, 
we assessed gene expression levels of TP53 and NOTCH1, two of the most altered genes in 
HNSCC, as well as that of MET, the receptor of hepatocyte growth factor (HGF) involved in 
the response to the anticancer agent cetuximab. Lastly, we measured mRNA levels of 
programmed death ligand 1 (PD-L1), a mediator of the immune response. The secondary aim 
is to determine any correlation between gene expression and clinical characteristics. 
Correlations with overall survival (OS) and disease-free survival (DFS) were analyzed as 
well. 
 
Materials and methods 
Patients and sample collection 
 One hundred patients surgically treated for HNSCC between January 2012 and 
September 2018 at Otorhinolaryngology Division of the University of Turin were enrolled in 
this study and evaluated for the presence of HPV. Exclusion criteria were the following: 
cancer of nasal cavities and nasopharynx, occult primary tumors, recurrent or second primary 
tumors, neoadjuvant chemotherapy, salvage surgery after radiation therapy or 
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chemoradiotherapy, tumor smaller than 1 cm in its maximum diameter (because the whole 
surgical sample was required for pathological examination), and distant metastases. The study 
sample included patients with carcinoma of oral cavity, oropharynx, larynx, and 
hypopharynx. HNSCC classification was based on the seventh edition of the American Joint 
Committee on Cancer (AJCC) staging system. 
 After surgical removal of the primary tumor, a portion of it (about 50-100 mg) and a 
sample of macroscopically healthy surrounding mucosa were isolated for molecular analyses. 
Patients underwent adjuvant treatments when adverse features were present at histology, 
according to national and international guidelines [5]. 
 All procedures were in accordance with the ethical standards of the institutional 
research committee and with the 1964 Helsinki declaration and its later amendments or 
comparable ethical standards. Written informed consent was obtained from each patient. This 
study was approved by the Research Ethics Committee of the University Hospital of Turin 
“A.O.U. Città della Salute e della Scienza di Torino–A.O. Ordine Mauriziano–A.S.L. Città di 
Torino” as well. 
 Ten HPV+ HNSCCs (10% of all cases) were identified. They were analyzed for 
mRNA expression levels of selected biomarkers. Twenty-four consecutive HPV- HNSCC 
patients were included in the study to assess the differences in mRNA expression levels. 
Therefore, molecular biomarkers were evaluated in a total of 34 HNSCC patients. Table 1 
reports clinical characteristics of the two patient groups. Mean follow-up was 19.79 ± 8.05 
months (range 7-36 months). 
 
HPV detection 
 PCR analysis was carried out on tumor and mucosa DNA samples. The TRI Reagent® 
(Sigma-Aldrich, St. Louis, Missouri, USA) extraction kit was used for the simultaneous 
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extraction of DNA and RNA according to the manufacturer’s protocol. DNA integrity was 
confirmed upon amplification of β-globin by PC04 and GH20 primers (Table 2). HPV DNA 
analysis was performed by nested PCR assay, using MY09-MY11 as the outer primers and 
GP5+-GP6+ as the inner primers (Table 2). The outer primer pair was specific for a conserved 
approximately 450 base-long sequence contained within the L1 gene, while the inner primers 
amplified a 150 base-long sequence within the sequence amplified by the first PCR assay 
[24,25]. All PCR reactions were carried out using REDTaq ReadyMix PCR Reaction Mix 
(Sigma, St. Louis, MO, USA) (Table 2). Finally, 15 μl of the PCR reaction mixtures were 
electrophoresed through a 1.8% agarose gel containing 0.5 μg/mL ethidium bromide and then 
visualized under an ultraviolet transilluminator. 
 
RNA extraction and RT-qPCR analysis 
 To evaluate gene expression, RNA was extracted by TRI Reagent® (Sigma-Aldrich, 
St. Louis, Missouri, USA) extraction kit and 1 μg of RNA was retrotranscribed using the 
Revert-Aid H-Minus FirstStrand cDNA Synthesis Kit (Thermo Fisher Scientific, Waltham, 
Massachusetts, USA), according to the manufacturer’s protocol. Quantification of mRNA 
expression in tumor and healthy mucosa samples was carried out using SYBR green-based 
RT-qPCR on a Mx3000P apparatus (Stratagene). Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as the housekeeping gene. Table 3 reports the primers used in RT-qPCR. 
The 2-ΔΔCt method was applied to analyze the relative changes in gene expression from RT-
qPCR experiments in the tumor tissue compared to the healthy mucosa from the same patient 
[26]. Gene expression classification was carried out according to Rusz et al. [27]. Briefly, a 
gene whose mRNA expression levels were found to be >2 times higher than those observed in 
surrounding healthy mucosa was classified as upregulated; if the values were <0.5 times or 
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between 0.5 and 2 times, the genes were classified as downregulated or unchanged, 
respectively. 
 
Statistical analysis 
 All statistical analyses were carried out using Statistical Package for Social Sciences 
(SPSS), version 20.0, and GraphPad Prism, version 5. A descriptive analysis of all data was 
performed, and the data were reported as means or percentages and standard deviations. Since 
the Kolmogorov-Smirnov test demonstrated a non-Gaussian distribution of variables, 
nonparametric tests were used. The Mann-Whitney U test was employed to assess differences 
between groups in the mean of continuous variables. The chi-square (χ2) or Fisher’s exact test 
was used for categorical variables and the Kaplan Meier method for the creation of OS and 
DFS curves. Curve comparison was performed using the log-rank test. All tests were two-
tailed. Adjustment for false discovery rate was used. A p value <0.05 was considered to be 
statistically significant.  
 
Results 
Patients and tumors characteristics 
 Table 1 shows the clinical characteristics of the HNSCC patients included in the study 
according to HPV status. Statistically significant differences were observed between the two 
groups in terms of alcohol consumption, smoke, and tumor site and stage (p<0.05 at χ2 test, n 
= 34). In good agreement with the literature [2], the percentage of smokers and drinkers 
among HPV+ patients was lower than that observed in HPV- patients (30% vs 79% for smoke, 
and  20% vs 67% for alcohol consumption, for HPV+ and HPV- patients, respectively). The 
oropharynx was the main tumor site among HPV+ patients (50% of cases), in good agreement 
with the notion that HPV affects this compartment more frequently than the oral cavity and 
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larynx. Finally, there were not stage IV tumors among HPV+ patients probably because they 
had undergone exclusive chemoradiation therapy according to national and international 
guidelines [5]. 
 Adjuvant treatment (i.e. radiotherapy or chemoradiotherapy) was administered in 50% 
and 40% of HPV- and HPV+ patients, respectively (p>0.05 at χ2test, n = 34). Positive margins 
were found in 21% and 20% of HPV- and HPV+ patients, respectively (p>0.05 at χ2 test, n = 
34). 
 
Gene expression of selected molecular markers correlates with HPV infection status 
 To determine potential correlations between HPV infection status and gene expression 
of selected biomarkers, we first measured mRNA expression levels by RT-qPCR in both the 
tumor tissue and the healthy mucosa from the same patient. Gene expression differences 
between these two compartments were then determined using the 2-ΔΔCt method as described 
in the Materials and Methods. According to this method, genes were divided into three 
distinct groups: upregulated, downregulated, or unchanged. Fig. 1 shows gene expression 
levels according to the HPV status of the tumor. Statistically significant differences between 
HPV- and HPV+ HNSCCs (p<0.05 at χ2test, n = 34) were observed for IFI16, AIM2, A3A, 
and A3B (Table 4, Fig. 1). Indeed, IFI16, A3A, and A3B were predominantly downregulated 
in HPV- HNSCCs, while they were found upregulated in HPV+ HNSCCs. This trend was 
particularly evident for IFI16 and A3B. Interestingly, AIM2 was four times more likely to be 
found as unchanged in HPV+ HNSCCs compared to HPV- HNSCCs, with a slightly higher 
percentage of these latter displaying AIM2 upregulation. 
 The other biomarkers did not show any significant differences (p>0.05 at χ2test, n = 
34). However, some genes displayed different expression patterns in HPV- vs. HPV+ 
HNSCCs. In particular, PD-L1 was more consistently found upregulated in HPV+ vs. HPV- 
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tumors. In contrast, A3H was predominantly downregulated in HPV+ tumors. Finally, MET 
was among the most highly expressed genes in either group.  
 
Relationships between gene expression and clinical characteristics 
 Next, we sought to determine any correlation between gene expression of selected 
biomarkers and the patients’ clinical characteristics. To this end, we analyzed HPV+ and HPV- 
tumors separately to avoid a bias due to the fact that HPV infection correlated with tumor site 
and stage (Table 1). In HPV- HNSCCs, a higher expression level of TP53, NOTCH1, and 
IFI16 correlated with a lower percentage of nodal metastases (p<0.05 χ2 = 7.71, 6.62, and 
6.17, respectively; n = 24) (Table 5, Fig. 2). Moreover, HPV- patients without nodal 
metastases showed a higher expression of PD-L1 (p<0.05 χ2 = 6.90; n = 24) (Table 5, Fig. 2). 
In HPV- HNSCCs, higher TP53 expression levels were observed in early stage tumors (I-II) 
(p<0.05; χ2 = 7.40; n = 24), whereas no correlation with tumor site, T status, or grading was 
observed. Moreover, gene expression of any APOBEC family members did not correlate with 
clinical characteristics. Lastly, in the HPV+ group, there was not any statistically significant 
correlation with clinical characteristics (p>0.05 at χ2test, n = 10). 
 
Correlation among gene expression levels 
 We next asked whether there could be any correlation among the mRNA expression 
levels of APOBEC family members and the other genes so far examined. In HPV- HNSCCs, 
we could find statistically significant correlations (p<0.05) between: 1) TP53 expression and 
A3A and A3F expression (χ2 = 9.98 and 11.63, respectively; n = 24); 2) NOTCH1 expression 
and A3B and A3F expression (χ2 = 12.73 and 12.14, respectively; n = 24); and 3) PD-L1 
expression and A3A expression (χ2 = 9.55; n = 24) (Table 6). In HPV+ HNSCC, the following 
correlations (p<0.05) were observed between: 1) MET expression and A3A expression (χ2 = 
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10.40; n = 10); 2) PD-L1 expression and A3F expression (χ2 = 16.40; n = 10); and 3) IFI16 
expression and A3A expression (χ2 = 10.03; n = 10) (Table 6). In all cases, higher expression 
levels of the APOBEC gene were associated with higher expression levels of the other gene, 
indicating that these correlations were positive. After adjustment for false discovery rate, only 
the correlation between PD-L1 expression and A3F expression remained significant. 
 
Survival analysis 
 Next, we sought to determine the prognostic value of the selected biomarkers. Firstly, 
we compared the OS and DFS of HPV- HNSCC patients to those of HPV+ HNSCC patients. 
In good agreement with the literature [2], we found a better OS and DFS for HPV+ patients 
(Fig. 4). However, this trend was not statistically significant at log-rank test (p=0.418 for OS, 
and p=0.498 for DFS), probably because of the small number of patients and a mean follow-
up < 3 years. Since the HPV+ group comprised only a small number of patients (n=10), 
further survival analyses were performed only in the HPV- group (Table 7). 
 According to previous results [5], patients without nodal metastases had a better OS 
and DFS (Fig. 5). Probably due to of the small sample size, this trend was not statistically 
significant at log-rank test (Table 7). Figures 6 and 7 show OS and DFS curves according to 
gene expression levels in the HPV- group. Significance was only observed for A3F and A3H 
expression (Table 7). Interestingly, patients displaying upregulated A3F had a worse 
prognosis. A similar but not significant trend was observed for A3C. On the other hand, 
patients without changes in A3H expression had lower OS and DFS (Fig. 7). Lastly, patients 
with downregulated PD-L1, IFI16, and AIM2 seemed to have a worse prognosis (p>0.05), 
especially when considering OS (Fig. 6). 
 
Discussion 
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 HNSCC has an estimated incidence of about 16 new cases per 100,000 people, with a 
male to female ratio of approximately 2:1 [1]. According to the Surveillance, Epidemiology 
and End Results (SEER) database, there was an increase in incidence of oropharyngeal 
carcinomas from 1973 to 2001 in younger U.S. people (20-44 year-old), while the incidence 
of carcinomas in other oral and pharyngeal subsites remained constant [28]. This rise in the 
incidence of oropharyngeal carcinomas has been associated with the presence of HPV [29]. 
High-risk HPV types represent a risk factor for HNSCC independent of traditional risk factors 
such as tobacco and alcohol abuse. [30,31]  
 HPV- and HPV+ HNSCCs have different prognoses and molecular profiles [7]. In the 
last decades, a number of genes have been shown to display different mutation and gene 
expression patterns in HPV- vs HPV+ HNSCCs. For instance, TP53 mutations are the most 
frequent abnormalities found in HPV- HNSCC [32,33]. Furthermore, TP53 mutations occur in 
30-75% of HNSCCs and correlate with poor survival in invasive carcinomas [34,35,36]. The 
second most frequently mutated gene in HNSCC (14-15% of cases) is NOTCH1, a key player 
in normal cell differentiation, lineage commitment, and embryonic development. Enhanced 
expression levels of downstream NOTCH1 effectors have been found in 32% of HNSCCs 
[37], suggesting a pro-tumorigenic role of this gene in HNSCC pathogenesis [38]. In contrast, 
recent exome sequencing analyses have proposed a tumor suppressor role for NOTCH1 
because of loss-of-function mutations found in a high percentage of patients [39]. Thus, 
further gene sequencing analyses will help clarify this important issue also in our cohort of 
patients. 
 Other mutated genes found in HNSCC, like MET, are also involved in the response to 
radiotherapy or chemotherapy and are known biomarkers of lymph node and distant 
metastases. Furthermore, MET and/or HGF are over-expressed in about 80% of HNSCC [37, 
40,  41].  
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Finally, several mutated genes have been involved in the immunologic response to 
cancer. Among these, PD-L1 is a surface glycoprotein which induces T-cell anergy or 
apoptosis by binding to PD-1 on tumor infiltrating T lymphocytes [42]. PD-L1 
overexpression has been observed in 61-71% of oropharyngeal carcinomas regardless of HPV 
status [43]. Inhibition of the PD-1:PD-L1 interaction with specific antibodies (i.e. immune-
checkpoint inhibitors) is a promising antitumor treatment in patients with HNSCC, non-small 
cell lung cancer, and melanoma [43,44,45]. 
 With regard to the aforementioned TP53, NOTCH1, MET, and PD-L1, our study does 
not show any statistically significant difference in gene expression between HPV- and HPV+ 
HNSCCs. Their expression patterns are, for the most part, in agreement with those described 
in the literature. MET was confirmed as the most frequently expressed gene, being detected in 
about 50-60% in our case series. In HPV- tumors, TP53 and NOTCH1 negatively correlate 
with the presence of nodal metastases. In addition, TP53 appears to be negatively associated 
with tumor stage. These findings are consistent with the tumor suppressor role played by 
these genes in HNSCC pathogenesis [39]. A near significant direct association between MET 
and nodal metastases is in agreement with the literature [40]. In HPV- tumors, PD-L1 showed 
a more complex relationship with nodal status. In fact, patients with nodal metastases had a 
lower percentage of tumors over-expressing PD-L1, in agreement with its role in evading 
immune response [42]. The remaining patients with nodal metastases mainly showed no 
changes in PD-L1 expression, thereby demonstrating a non-linear relationship. Thus, further 
studies on the complex interactions between tumor and immune system are clearly needed to 
better understand the clinical significance of our PD-L1 findings. 
 The role of PYHIN and APOBEC family member in HNSCC has only emerged in 
recent years [11,12,13,14,46]. In particular, co-expression of IFI16 and AIM2 was shown to 
enhance the cell growth in p53-deficient cells. By contrast, expression of IFI16 and/or AIM2 
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in cells with wild-type p53 suppresses the cell growth. Moreover, IFI16 and AIM2 
synergistically enhanced NF-κB signaling in p53-deficient cells. Therefore, the expression of 
IFI16 and AIM2 appears to have oncogenic activities in tumor cells where p53 is inactivated 
[48]. However, the relationship between AIM2 expression and HPV infection has never been 
evaluated. 
 Here, we show a predominant upregulation of IFI16 in HPV+ vs HPV- tumors, in good 
agreement with the literature and consistent with its role as a viral restriction factor [47]. On 
the other hand, AIM2 was mainly upregulated in HPV- HNSCC, while 50% of HPV+ tumors 
showed no changes in AIM2 expression level. A previous study demonstrated aberrant 
expression of AIM2 in oral carcinomas, without looking at HPV infection status [48]. Since 
oral carcinomas rarely show HPV positivity, our results are likely to be consistent with the 
findings of the aforementioned study. The unexpected lack of overexpression of an 
intracellular sensor of viral DNA, like AIM2, in HPV+ HNSCCs, which may relate to its 
predominant role in inflammasome regulation, warrants further investigation. Interestingly, 
IFI16 expression negatively correlated with nodal metastases in HPV- HNSCCs, suggesting a 
protective role against the lymphatic diffusion of tumor cells also in the absence of HPV 
infection. The possible reason could be found in the regulation of some transcription factors, 
as demonstrated in differentiating B cells [49]. Our study seems to confirm a protective role 
for IFI16, in agreement with previous studies in vitro and in vivo [11,47], although further 
studies are required to further substantiate this hypothesis.  
Finally, no significant correlation between IFI16 or AIM2 expression and clinical 
characteristics was observed in HPV+ tumors. However, further studies with larger number of 
samples are clearly needed to generalize our findings. 
 Whereas the function of APOBEC deaminases in infection is well defined, their role in 
carcinogenesis has only recently emerged [16]. A3B is involved in HPV+ HNSCC by 
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determining a peculiar mutational signature. In contrast, HPV- tumors display a smoking-
associated mutational signature. APOBEC activity induces helical domain hot spot mutations 
in the PIK3CA gene in HPV+ HNSCC [23]. More recently, A3A has also been found 
overexpressed in HPV+ oropharyngeal tumors [50]. Furthermore, enhanced A3A expression is 
associated with better overall survival in patients with oral cancer carrying A3B-deletion 
alleles [51]. 
 Our study confirms the predominant role of overexpressed A3A and A3B in HPV+ 
HNSCC. The percentages of patients characterized by overexpression of these two cytidine 
deaminases were 50% and 70%, respectively. The other APOBEC3 genes did not show any 
statistically significant difference in relation to HPV status, suggesting a weak role in head 
and neck carcinogenesis. None of the APOBEC3 genes showed any correlation with clinical 
characteristics (i.e. tumor site, T, N, stage, and grading) regardless of HPV status. However, 
the small number of patients in HPV+ group may represent a limitation of our study. Only a 
few correlations between APOBEC3 expression levels and the other analyzed biomarkers 
were observed. These results are in line with the mutational activity of cytidine deaminases, 
which likely does not affect gene expression. 
 The survival analyses showed a better prognosis for HPV+ HNSCC and for patients 
without nodal metastases (N0) , in agreement with the literature [2,5]. In this regard, the small 
sample size could represent a confounding factor that should be taken into account in 
subsequent survival analyses. When we evaluated patient survival in the HPV- group, 
statistical significance for OS and DFS was achieved only for A3F and A3H genes. 
Specifically, patients characterized by A3F upregulation had a worse prognosis. On the other 
hand, patients without changes in A3H expression had lower OS and DFS. Our findings differ 
from those by Gao et al., showing a positive correlation between A3B, A3C, A3D, A3G, and 
A3H gene expression and survival in cervical cancer [52]. However, given that cervical 
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cancer is an HPV-related tumor and that our findings on A3F and A3H were obtained in HPV 
negative tumors, the disagreement between these two studies could be ascribed to the 
different HPV status of the tumors analyzed.  
Of note, patients showing downregulation of PD-L1, IFI16, and AIM2 genes seemed 
to have a worse prognosis, especially in terms of OS. However, since patients without nodal 
metastases have a better prognosis, the correlation between nodal metastases and IFI16/PD-
L1 could represent a confounding factor in such survival analyses.  
With regard to TP53, since this gene is often mutated in HPV- HNSCC, further studies 
taking into account both TP53 mutations and expression levels are clearly required to better 
understand its prognostic role. Furthermore, the upregulation of some APOBEC3 proteins in a 
percentage of HPV- patients and their possible influence on survival should be further 
addressed in studies with a larger number of patients in order to better assess their prognostic 
value. 
 In conclusion, our findings are suggestive of a potential role of PYHIN and APOBEC 
family members as prognostic markers of HNSCC regardless of HPV infection status. Future 
studies are clearly needed to determine the predictive value of these biomarkers for response 
to surgery and chemoradiation therapy, which would then provide the rationale for HPV+ 
patient treatment deintensification trials. 
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Figure legends 
Fig. 1 Different patterns of gene expression in HPV- and HPV+ HNSCCs. RNA samples 
from tumor tissues or healthy mucosa were subjected to RT-qPCR to measure gene 
expression levels of selected biomarkers. Values were normalized to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The HPV status was determined by 
nested PCR assays, using MY09-MY11 as the outer and GP5+-GP6+ as the inner primers on 
DNA obtained on the same samples (Table 2). Genes were classified as upregulated, 
downregulated or unchanged according to the differences in mRNA expression levels 
between the tumor and the surrounding healthy mucosa as described in the Materials and 
Methods. Asterisks refer to statistically significant differences between HPV- and HPV+ 
HNSCCs (*p<0.05, chi-square test, A vs C, and B vs D). 
 
Fig. 2 Gene expression of selected biomarkers in patients with or without nodal 
metastases. RNA samples from tumor tissues or healthy mucosa were subjected to RT-qPCR 
to measure gene expression of TP53 (A), NOTCH1 (B), PD-L1 (C), and IFI16 (D). Values 
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were normalized to GAPDH. Gene expression was classified as described in the legend to 
Fig. 1. N0 = patients without nodal metastases; N+ = patients with nodal metastases. 
 
Fig. 3 Higher TP53 gene expression in early stages (I-II) of tumor progression. RNA 
samples from tumor tissues or healthy mucosa were subjected to RT-qPCR to measure TP53 
mRNA expression levels. Values were normalized to GAPDH (p<0.05 at chi-square test, 
comparing early to late stages). 
 
Fig. 4 Overall survival and disease free survival for HPV- and HPV+ HNSCC patients. 
(A) Overall survival (OS) was defined as the time from treatment to death due to any cause. 
(B) Disease free survival (DSF) was defined as the time from treatment to recurrence or death 
due to any cause. The Kaplan Meier method was employed for survival probability 
estimation. 
 
Fig. 5 OS and DSF for HPV- HNSCC patients with or without nodal metastases. OS (A) 
and DFS (B) were calculated as described in the legend to Fig. 4. The Kaplan Meier method 
was employed for survival probability estimation. N0 = patients without nodal metastases; N+ 
= patients with nodal metastases. 
 
Fig. 6 Prognostic value of selected biomarkers in HPV- HNSCCs. OS and DFS were 
calculated as described in the legend to Fig. 4. The Kaplan Meier method was employed for 
survival probability estimation. Gene expression analysis of the indicated biomarkers in HPV- 
HNSCC patients was carried out as described in the legend to Fig. 1. (A) TP53, (B) 
NOTCH1, (C) MET, (D) PD-L1, (E) IFI16, (F) AIM2. 
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Fig. 7 Correlation between OS/DSF and APOBEC3 family members in HPV- HNSCCs. 
OS and DFS were calculated as described in the legend to Fig. 4. The Kaplan Meier method 
was employed for survival probability estimation. Gene expression analysis of the indicated 
APOBEC3 family members in HPV- HNSCC patients was carried out as described in the 
legend to Fig. 1. (A) A3A, (B) A3B, (C) A3C, (D) A3D, (E) A3F, (F) A3G, (G) A3H. 
Table 1. Patients and tumors characteristics (number of patients, %). 
Table 2. Primers and amplification protocols for HPV detection. 
Table 3. Primers for RT-qPCR. 
Table 4. Correlation between gene expression and HPV status (p value at chi-square or 
Fisher’s exact test). 
Table 5. Correlation between gene expression and clinical characteristics (p value at chi-
square or Fisher’s exact test) in HPV- and HPV+ tumors. 
Table 6. Correlation among APOBECs expression and other genes (p value at chi-square or 
Fisher’s exact test) in HPV- and HPV+ tumors. 
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Survival) in HPV- patients. 
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Table 1. Patients and tumors characteristics (number of patients, %). 
 
      HPV-                   HPV+              p value 
 
Age (mean ± st. dev.)  63.88 ± 13.20 years 60.90 ± 13.52 years 0.491 
Sex 
Male    18 (75)     6 (60)   0.875 
Female     6 (25)     4 (40) 
Alcohol consumption 
   Yes    16 (67)      2 (20)   0.010 
   No      8 (33)      8 (80) 
Smoke 
Yes    19 (79)      3 (30)   0.009 
No      5 (21)      7 (70) 
 
Site 
Oral cavity   15 (63)      4 (40)   0.005 
Oropharynx     2 (8)      5 (50) 
Larynx     7 (29)      1 (10) 
Tumor (T) 
T1      6 (25)      2 (20)   0.279 
T2      8 (33)      7 (70) 
T3      4 (17)      2 (20) 
T4a      6 (25)      0 (0) 
Nodes (N) 
N0    10 (42)      4 (40)   0.141 
N1      9 (37)      4 (40) 
N2       5 (21)      2 (20) 
N3      0 (0)      0 (0) 
Metastases (M) 
M0    24 (100)   10 (100)   1.000 
M1      0 (0)      0 (0) 
Stage 
I       5 (21)      0 (0)   0.017 
II      3 (12)      4 (40) 
III       7 (29)      6 (60) 
IV A      9 (38)      0 (0) 
Grading 
G1      1 (4)      0 (0)   0.654 
G2     11 (46)      6 (60) 
G3    12 (50)      4 (40) 
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Table 2. Primers and amplification protocols for HPV detection. 
 
  Primer sequences     Tm  Amplicon 
length 
 
β-globin  PC04 (Fw): 5'-CAACTTCATCCACGTTCACC-3'  55°C  268 bp 
  GH20 (Rw): 5'-GAAGAGCCAAGGACAGGTAC-3' 
 
L1 outer primers MY09 (Fw): 5'-CGTCCMARRGGAWACTGATC-3' 50°C  450 bp 
  MY11 (Rw): 5'-GCMCAGGGWCATAAYAATGG-3' 
 
L1 inner primers GP5+ (Fw): 5'-TTTGTTACTGTGGTAGATACTAC-3' 56°C  150 bp 
  GP6+ (Rw): 5'-GAAAAATAAACTGTAAATCATATT-3' 
 
 
Tm = melting temperature 
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Table 3. Primers for RT-qPCR. 
 
  Primer sequences    Tm  Amplicon length 
 
GAPDH Fw: 5'-AGTGGGTGTCGCTGTTGAAGT-3' 62°C  160 bp 
  Rw: 5'-AACGTGTCAGTGGTGGACCTG-3' 
TP53  Fw: 5'- CCCTTCCCAGAAAACCTACC-3' 57°C  223 bp 
  Rw: 5'-CTCCGTCATGTGCTGTGACT-3' 
NOTCH1 Fw: 5'-GGGTCCACCAGTTTGAATGG-3'  58°C  306 bp 
  Rw: 5'-GTTTGCTGGCTGCAGGTTCT-3' 
MET  Fw: 5'-AGCACTGCTTTAATAGGACAC-3' 56°C  226 bp 
  Rw: 5'-GATCGAGAAACCACAACCTG-3' 
PD-L1  Fw: 5'-CAATGTGACCAGCACACTGAGAA-3' 60°C  179 bp 
  Rw: 5'-GGCATAATAAGATGGCTCCCAGAA-3' 
IFI16  Fw: 5'-ACTGAGTACAACAAAGCCATTTGA-3' 59°C  432 bp 
  Rw: 5'-TTGTGACATTGTCCTGTCCCCAC-3' 
AIM2  Fw: 5'-AAGAAGGCAAGCAGGAGATG-3' 57°C  215 bp 
  Rw: 5'-GTTCAGCGGGACATTAACCT-3' 
APOBEC3A Fw: 5'-GAGAAGGGACAAGCACATGG-3' 56°C  61 bp 
  Rw: 5'-TGGATCCATCAAGTGTCTGG-3' 
APOBEC3B Fw: 5'-AATGTGTCTGGATCCATCAGG-3' 56°C  105 bp 
  Rw: 5'-TGAAGGTCAGCAATTCATGC-3' 
APOBEC3C Fw: 5'-TCTGCATGACAATGGGTCTC-3'  57°C  109 bp 
  Rw: 5'-AAACTTGGCTGTGCTTCACC-3' 
APOBEC3D  Fw: 5'-GATCTGGAAGCGCCTGTTAG-3'  58°C  110 bp 
  Rw: 5'-AGTCGAATCACAGGCAGGAG-3' 
APOBEC3F Fw: 5'-CCATAGGCTTTGCGTAGGTT-3'  57°C  110 bp 
  Rw: 5'-AATTATGCATTCCTGCACCG-3' 
APOBEC3G Fw: 5'-TTCCAAAAGGGAATCACGTC-3'  56°C  95 bp 
  Rw: 5'-AGGGGCTTTCTATGCAACC-3' 
APOBEC3H Fw: 5'-AGCTGTGGCCAGAAGCAC-3'  56°C  61 bp 
  Rw: 5'-CGGAATGTTTCGGCTGTT-3' 
 
 
Tm = melting temperature 
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Table 4. Correlation between gene expression and HPV status (p value at chi-square or 
Fisher’s exact test). 
 
   p value 
 
TP53   0.952 
NOTCH1  0.391 
MET   0.099 
PD-L1   0.429 
IFI16   0.034 
AIM2   0.023 
A3A   0.040 
A3B   0.048 
A3C   0.785 
A3D   0.151 
A3F   0.203 
A3G   0.707 
A3H   0.142 
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Table 5. Correlation between gene expression and clinical characteristics (p value at chi-
square or Fisher’s exact test) in HPV- and HPV+ tumors. 
 
HPV-  tumors 
 
  TP53  NOTCH1 MET  PD-L1  IFI16  AIM2 
 
Tumor site 0.479  0.496  0.616  0.737  0.392  0.872 
T  0.468  0.740  0454  0.739  0.072  0.310 
N  0.021  0.036  0.061  0.032  0.046  0.966 
Stage  0.025  0.477  0.459  0.200  0.264  0.315 
Grading  0.771  0.819  0.751  0.663  0.645  0.828 
 
  A3A A3B A3C A3D A3F A3G A3H 
 
Tumor site 0.726 0.880 0.948 0.075 0.385 0.742 0.594 
T  0.480 0.353 0.116 0.055 0.930 0.235 0.800 
N  0.408 0.537 0.550 0.226 0.796 0.212 0.105 
Stage  0.604 0.243 0.358 0.227 0.862 0.568 0.762 
Grading  0.789 0.323 0.097 0.566 0.220 0.318 0.521 
 
HPV+ tumors 
 
  TP53  NOTCH1 MET  PD-L1  IFI16  AIM2 
 
Tumor site 0.759  0.586  0.128  0.521  0.446  0.612
  
T  0.287  0.596  0.695  0.558  0.666  0.695
  
N  0.435  0.217  0.143  0.392  0.240  0.405
  
Stage  0.732  0.870  0.143  0.392  0.240  0.933
  
Grading  0.732  0.517  0.329  0.392  0.679  0.329 
 
  A3A A3B A3C A3D A3F A3G A3H 
 
Tumor site 0.116 0.833 0.123 0.240 0.298 0.759 0.558  
T  0.558 0.582 0.155 0.349 0.255 0.287 0.596 
N  0.082 0.679 0.153 0.108 0.287 0.732 0.435 
35 
 
Stage  0.392 0.679 0.435 0.435 0.392 0.732 0.435 
Grading  0.659 0.240 0.054 0.108 0.170 0.732 0.870 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6. Correlation among APOBECs expression and other genes (p value at chi-square or 
Fisher’s exact test) in HPV- and HPV+ tumors. 
 
HPV- tumors 
 
  TP53  NOTCH1 MET  PD-L1  IFI16  AIM2 
 
A3A  0.041  0.302  0.400  0.049  0.331  0.942 
A3B  0.239  0.013  0.259  0.054  0.351  0.299 
A3C  0.332  0.406  0.343  0.769  0.752  0.738 
A3D  0.255  0.498  0.549  0.562  0.695  0.647 
A3F  0.020  0.016  0.183  0.063  0.363  0.558 
A3G  0.186  0.194  0.404  0.466  0.270  0.433 
A3H  0.878  0.357  0.279  0.610  0.126  0.066 
 
HPV+ tumors 
 
  TP53  NOTCH1 MET  PD-L1  IFI16  AIM2 
 
A3A  0.579  0.622  0.034  0.541  0.040  0.231 
A3B  0.169  0.513  0.546  0.351  0.277  0.403 
A3C  0.870  0.472  0.530  0.251  0.392  0.287 
A3D  0.645  0.191  0.695  0.558  0.666  0.109 
A3F  0.759  0.092  0.612  0.003  0.369  0.107 
A3G  0.181  0.057  0.123  0.263  0.104  0.123 
A3H  0.155  0.349  0.155  0.558  0.582  0.695 
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Table 7. p values at log-rank test for curve comparison (Overall Survival and Disease Free 
Survival) in HPV- patients. 
 
   OS  DFS 
 
N status (N0 vs N+) 0.202  0.220 
TP53   0.793  0.598 
NOTCH1  0.542  0.953 
MET   0.609  0.470 
PD-L1   0.099  0.348 
IFI16   0.643  0.565 
AIM2   0.298  0.247 
A3A   0.735  0.674 
A3B   0.787  0.518 
A3C   0.052  0.210 
A3D   0.636  0.273 
A3F   0.038  0.004 
A3G   0.551  0.776 
A3H   0.023  0.016 
 
 
 
